1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea
• 英文别名: 1-[2-methoxy-5-(trifluoromethyl)phenyl]-3-[3-[8-(2-pyridin-4-ylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
• 化学式: C₂₉H₂₁F₃N₈O₂
• 分子量: 570.5
• InChiKey: FSWSDBNGXSCJAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-[6-Bromo-8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenylamine 、 2-甲氧基-5-三氟甲基异氰酸苯酯 、 N,N-二甲基甲酰胺 以 二氯甲烷 为溶剂， 反应 16.0h， 以to give 1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea (6) (468 mg) as a white solid的产率得到1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea
  参考文献：
  名称：

  Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity

  摘要：

  本发明涉及公式I的化合物及其所有药学上可接受的形式。公式I中所示的变量R1、R2、R3、Z1、Z2、W和X在此定义。本发明还提供了含有一种或多种公式I化合物或其药学上可接受的形式以及一种或多种药学上可接受的载体、辅料或稀释剂的制药组合物。本发明还包括治疗对EphB4激酶调节有反应的某些疾病和疾病的患者的方法，其中包括向这些患者施用足够的公式I化合物的量，以减少疾病或疾病的症状或症状。这些疾病包括癌症，包括乳腺肿瘤、子宫内膜癌、结肠癌和颈部鳞状细胞癌。因此，治疗方法包括施用足够的该发明的化合物或盐以减少这些疾病或疾病的症状或减缓其进展。本发明还包括治疗其他动物，包括家畜和驯养伴侣动物，患有对EphB4调节有反应的疾病或疾病的方法。治疗方法包括将公式I化合物作为单一活性剂或与一种或多种其他治疗剂联合使用。本发明还包括一种用于确定样品中EphB4激酶存在的方法，包括将样品与公式I化合物或其形式接触，并检测与EphB4激酶结合的化合物或形式的量，并从中确定样品中EphB4激酶的存在或缺失。

  公开号：

  US07189723B2

文献信息

• US7189723B2
  申请人：——

  公开号：US7189723B2

  公开（公告）日：2007-03-13
• [EN] CERTAIN 8-HETEROARYL-6-PHENYL-IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY<br/>[FR] 8-HETEROARYLE-6-PHENYLE-IMIDAZO[1,2-A]PYRAZINES COMME MODULATEURS DE L'ACTIVITE KINASE
  申请人：CELLULAR GENOMICS INC

  公开号：WO2004072081A1

  公开（公告）日：2004-08-26

  This invention pertains to compounds of Formula I: (I) and all pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound or salt of the invention to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to EphB4 modulation. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent. The invention also includes a method for determining the presence of EphB4 kinase in a sample, comprising contacting the sample with a compound of Formula I, or form thereof, and detecting the amount of compound or form bound to EphB4 kinase, and therefrom determining the presence or absence of EphB4 kinase in the sample.
• Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
  申请人：Mitchell A. Scott

  公开号：US20050054648A1

  公开（公告）日：2005-03-10

  This invention pertains to compounds of Formula I: and all pharmaceutically-acceptable forms thereof. The variables R 1 , R 2 , R 3 , Z 1 , Z 2 , W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound or salt of the invention to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an disease or disorder responsive to EphB4 modulation. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent. The invention also includes a method for determining the presence of EphB 4 kinase in a sample, comprising contacting the sample with a compound of Formula I, or form thereof, and the detecting the amount of compound or form bound to EphB 4 kinase, and therefrom determining the presence or absence of EphB 4 kinase in the sample.

  本发明涉及公式I的化合物及其所有药学上可接受的形式。公式I中所示的变量R1、R2、R3、Z1、Z2、W和X在此定义。该发明还提供含有公式I的一个或多个化合物或其药学上可接受的形式以及一个或多个药学上可接受的载体、辅料或稀释剂的制剂。该发明还包括治疗患有对EphB4激酶调节有反应的某些疾病和疾病的患者的方法，其中包括向这些患者施用公式I的化合物的有效量，以减少疾病或疾病的症状。这些疾病包括癌症，包括乳腺肿瘤、子宫内膜癌、结肠癌和颈部鳞状细胞癌。因此，治疗方法包括施用足够量的公式I的化合物或盐以减轻这些疾病或疾病的症状或减缓其进展。该发明还包括治疗其他动物，包括家畜和驯养伴侣动物，患有对EphB4调节有反应的疾病或疾病的方法。治疗方法包括将公式I的化合物作为单一活性药物施用或将公式I的化合物与一个或多个其他治疗剂联合施用。该发明还包括一种确定样品中EphB4激酶存在的方法，包括将样品与公式I的化合物或其形式接触，并检测与EphB4激酶结合的化合物或形式的数量，从而确定样品中EphB4激酶的存在或不存在。